I think dark horse is appropriate. The concerns I heard are actually the convenience of dosing schedule. MS isn't a disease you take a drug once a year, then you can forget about it. The neurologists are actually concerned about the irreversibility of once a year dosing. If something is wrong, you can't simply stop taking the drug because it "induces long term if not permanent changes in immunoregulation."
I think people need to be careful in projecting MS market share until the drug is on the market for a few years.
Market Data 
Markets 
AI
